92 related articles for article (PubMed ID: 34830747)
1. Influence of
Porpaczy E; Wohlfarth P; Königsbrügge O; Rabitsch W; Skrabs C; Staber P; Worel N; Müllauer L; Simonitsch-Klupp I; Kornauth C; Rohrbeck J; Jaeger U; Schiefer AI
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830747
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
Zhou LH; Feng YQ; Hu YX; Huang H
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
[No Abstract] [Full Text] [Related]
3. Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy.
Li Y; Liu Y; Yang K; Jin L; Yang J; Huang S; Liu Y; Hu B; Liu R; Liu W; Liu A; Zheng Q; Zhang Y
Cancer Cell Int; 2023 Nov; 23(1):281. PubMed ID: 37981695
[TBL] [Abstract][Full Text] [Related]
4. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies.
Sermer D; Batlevi C; Palomba ML; Shah G; Lin RJ; Perales MA; Scordo M; Dahi P; Pennisi M; Afuye A; Silverberg ML; Ho C; Flynn J; Devlin S; Caron P; Hamilton A; Hamlin P; Horwitz S; Joffe E; Kumar A; Matasar M; Noy A; Owens C; Moskowitz A; Straus D; von Keudell G; Rodriguez-Rivera I; Falchi L; Zelenetz A; Yahalom J; Younes A; Sauter C
Blood Adv; 2020 Oct; 4(19):4669-4678. PubMed ID: 33002134
[TBL] [Abstract][Full Text] [Related]
5. CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement.
Shumilov E; Boyadzhiev H; Mazzeo P; Akhoundova D; Daskalakis M; Novak U; Lenz G; Bacher U; Pabst T
Hemasphere; 2023 Dec; 7(12):e984. PubMed ID: 38044958
[TBL] [Abstract][Full Text] [Related]
6. Integrative analyses reveal outcome-associated and targetable molecular partnerships between TP53, BRD4, TNFRSF10B, and CDKN1A in diffuse large B-cell lymphoma.
Forberg AL; Unrau J; Weber KS; Rutz AC; Lund S; Guidinger J; Pelzel A; Hauge J; Hemmen AJ; Hartert KT
Ann Hematol; 2024 Jan; 103(1):199-209. PubMed ID: 37792064
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Refractory p53 Mutation Large B-cell Lymphoma with Daratumumab and Venetoclax Followed by CAR-T Cell Therapy: Case Report and Animal Study.
Gong D; Gu J; Zhou K; Huang W
Recent Pat Anticancer Drug Discov; 2024 Jan; ():. PubMed ID: 38265376
[TBL] [Abstract][Full Text] [Related]
8. Integrative genomic analysis identifies unique immune environments associated with immunotherapy response in diffuse large B cell lymphoma.
Tumuluru S; Godfrey JK; Cooper A; Yu J; Chen X; MacNabb BW; Venkataraman G; Zha Y; Pelzer B; Song J; Duns G; Sworder BJ; Bolen C; Penuel E; Postovalova E; Kotlov N; Bagaev A; Fowler N; Smith SM; Alizadeh AA; Steidl C; Kline J
bioRxiv; 2024 Apr; ():. PubMed ID: 38328071
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a case report and literature review.
He J; Zou R; Kang L; Yu L; Wang P; Shao Y; Liang J; Wu D; Jin Z; Qu C
Front Oncol; 2023; 13():1283194. PubMed ID: 38090479
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology and Real-World Treatment of Incident Diffuse Large B-cell Lymphoma (DLBCL): A German Claims Data Analysis.
Pacis S; Bolzani A; Heuck A; Gossens K; Kruse M; Fritz B; Maywald U; Wilke T; Kunz C
Oncol Ther; 2024 Feb; ():. PubMed ID: 38379108
[TBL] [Abstract][Full Text] [Related]
11. The Clinical Significance of Circulating Lymphocytes Morphology in Diffuse Large B-Cell Lymphoma As Determined by a Novel, Highly Sensitive Microscopy.
Fridberg G; Horn G; Globerson Levin A; Benisty D; Kay S; Glait-Santar C; Perry C; Ram R; Avivi I; Katz BZ
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067314
[TBL] [Abstract][Full Text] [Related]
12. Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance.
Younes S; Zhao S; Bharadwaj S; Mosquera AP; Libert D; Johnsrud A; Majzner RG; Miklos DB; Frank MJ; Natkunam Y
Mod Pathol; 2023 Oct; 36(10):100256. PubMed ID: 37391168
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of relapsed/refractory double-hit lymphoma (r/r DHL) treated with CD19/22 CAR T-cell cocktail therapy.
Wei J; Mao Z; Wang N; Huang L; Cao Y; Sun W; Long X; Tan J; Li C; Xiao Y; Gu C; Zhang S; Zhang Y; Zhang T; Zhou J; Huang L
Clin Transl Med; 2020 Sep; 10(5):e176. PubMed ID: 32997409
[No Abstract] [Full Text] [Related]
14. Tips on choosing a CAR T-cell therapy in DLBCL.
Abramson JS
Clin Adv Hematol Oncol; 2023 Nov; 21(11):592-596. PubMed ID: 37948595
[No Abstract] [Full Text] [Related]
15. Impact of
Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML
J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572
[TBL] [Abstract][Full Text] [Related]
16. CAR T-cell therapy in large B cell lymphoma.
Boardman AP; Salles G
Hematol Oncol; 2023 Jun; 41 Suppl 1(Suppl 1):112-118. PubMed ID: 37294963
[TBL] [Abstract][Full Text] [Related]
17. Post-infusion CAR T
Good Z; Spiegel JY; Sahaf B; Malipatlolla MB; Ehlinger ZJ; Kurra S; Desai MH; Reynolds WD; Wong Lin A; Vandris P; Wu F; Prabhu S; Hamilton MP; Tamaresis JS; Hanson PJ; Patel S; Feldman SA; Frank MJ; Baird JH; Muffly L; Claire GK; Craig J; Kong KA; Wagh D; Coller J; Bendall SC; Tibshirani RJ; Plevritis SK; Miklos DB; Mackall CL
Nat Med; 2022 Sep; 28(9):1860-1871. PubMed ID: 36097223
[TBL] [Abstract][Full Text] [Related]
18. CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?
Kinoshita H; Bollard CM; Toner K
Semin Hematol; 2023 Nov; 60(5):329-337. PubMed ID: 38336529
[TBL] [Abstract][Full Text] [Related]
19. A nomogram for predicting the rapid progression of diffuse large B-cell lymphoma established by combining baseline PET/CT total metabolic tumor volume, lesion diffusion, and TP53 mutations.
Liu C; Shi P; Li Z; Li B; Li Z
Cancer Med; 2023 Aug; 12(16):16734-16743. PubMed ID: 37366281
[TBL] [Abstract][Full Text] [Related]
20. Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
Yuan X; Li X; Huang Y; Jin X; Liu H; Zhao A; Zhang W; Qian W; Liang Y
Front Immunol; 2022; 13():1015081. PubMed ID: 36505470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
